Shots:

• Inovio is currently evaluating INO-4800 vaccine in P-I study assessing its safety and immunogenicity in the US and is supported by a grant of ~$9M from the Coalition for Epidemic Preparedness Innovations (CEPI)
• The focus of the collaboration is to deploy Advaccine's expertise to initiate P-I study in China in parallel with its clinical study in the US. The companies will work together to attract additional funding and further collaborates with other companies to speed up the testing of INO-4800
• The collaboration allows Inovio to enter in China and deliver its vaccine to the patients. Additionally- Inovio will initiate P-II study for INO-4700 in the Middle East against MERS viral outbreak

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image:  Smarteranalyst